Drug Trial Radar · NCT04935177
Renal Function in Highly Sensitized Patients 1 Year After Desensitization With Imlifidase Prior to DD Kidney Tx
Last checked: Nov 19, 2026Latest source record: Apr 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
64
Actual
Start
Oct 14, 2021
Primary completion
Jun 20, 2025
Study completion Jun 20, 2025
Sponsor
- Lead sponsor
- Hansa Biopharma ABIndustry
- Sponsor type
- Industry
- First posted
- Jun 22, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
An open-label, controlled, randomized Phase 3 trial evaluating 12-month kidney function in highly sensitized (cPRA ≥99.9%) kidney transplant patients with positive crossmatch against a deceased donor, comparing desensitization using imlifidase with standard of care
Conditions
- Kidney Transplantation in Highly Sensitized Patients
Interventions
ImlifidaseDrug
Imlifidase is an immunoglobulin G (IgG)-degrading enzyme of Streptococcus pyogenes that is highly selective towards IgG. The cleavage of IgG generates one F(ab')2- and one homodimeric Fc-fragment and efficiently neutralizes Fc-mediated activities of IgG.
PLEXProcedure
PLEX is performed according to the respective site's standard procedure for desensitization.
IVIgDrug
IVIg prepared from a pool of immunoglobulins from the plasma of thousands of healthy donors is administered in accordance with respective site's standard procedure for desensitization.
Anti-CD20 antibodiesDrug
Rituximab and other anti-CD20 according to the respective site's standard procedure for desensitization.
EculizumabDrug
Eculizumab according to the respective site's standard procedure for desensitization.
Remain on wait listOther
Remain on wait list for a more compatible organ offer if desentization with institutional protocol is not appropriate
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean estimated glomerular filtration rate (eGFR) at 12 monthsTime frame: 12 months after randomization
Locations
25 sites in 1 country. Site status is shown where the registry gives one.
University of Alabama at Birmingham (UAB) Hospital
Birmingham, Alabama
Banner Health - University Medical Center - Phoenix
Phoenix, Arizona
Mayo Clinic Phoenix
Phoenix, Arizona
Keck Hospital of University of Southern California (USC)
Los Angeles, California
Cedars-Sinai Medical Center
Los Angeles, California
Sutter Health - California Pacific Medical Center
San Francisco, California
University of California San Francisco (UCSF) Medical Center
San Francisco, California
Georgetown Transplant Institute
Washington D.C., District of Columbia
Northwestern University
Chicago, Illinois
University of Chicago Medical Center
Chicago, Illinois
University of Iowa Hospitals and Clinics
Iowa City, Iowa
John Hopkins Hospital
Baltimore, Maryland
Massachusetts General Hospital
Boston, Massachusetts
University of Minnesota Medical School
Minneapolis, Minnesota
Mayo Clinic Rochester
Rochester, Minnesota
Washington University School of Medicine
St Louis, Missouri
Saint Barnabas Medical Center
Livingston, New Jersey
New York University (NYU) Langone Transplant Institute, NYU Langone Health
New York, New York
Columbia University
New York, New York
New York-Presbyterian - Weill Cornell Medical Center
New York, New York
Hospital of the University of Pennsylvania, Penn Medicine
Philadelphia, Pennsylvania
Houston Methodist Hospital
Houston, Texas
Methodist Hospital Specialty and Transplant
San Antonio, Texas
University of Washington Medical Center
Seattle, Washington
Medical College of Wisconsin
Milwaukee, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.